A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer is a phase 3 interventional study registered as NCT07284849, led by Incyte, and recruiting on the registry. Official title: A Randomised, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer. Planned enrolment is 700 participants (estimated). The study started in 2026-03-05 and primary completion is expected in 2028-12-29. No results have been posted on ClinicalTrials.gov.